{
    "organizations": [],
    "uuid": "1b5f8c3c5bc680c86f0cfd784842391ae9403887",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-corrected-veloxis-pharmaceuticals/brief-corrected-idUSL5N1SN7LQ",
    "ord_in_thread": 0,
    "title": "BRIEF-CORRECTED-(OFFICIAL)-Veloxis Pharmaceuticals maintains 2018 Outlook Of Revenues (May 14)",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Veloxis Pharmaceuticals A/S:\n* VELOXIS PHARMACEUTICALS - MAINTAINS ITS 2018 OUTLOOK OF OPERATING LOSS BEFORE ACCOUNTING FOR STOCK COMPENSATION IN RANGE OF USD 6 MILLIONâ€“12 MILLION\n* REG-VELOXIS PHARMACEUTICALS ANNOUNCES FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2018\n* QTRLY PRODUCT REVENUE FOR Q1 2018 WAS TUSD 7,265 AN INCREASE OF 142% COMPARED TO SAME PERIOD LAST YEAR\n* VELOXIS MAINTAINS ITS 2018 OUTLOOK OF REVENUES TO BE IN RANGE OF USD 32 MILLION- USD 40 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T06:26:00.000+03:00",
    "crawled": "2018-05-17T14:44:42.034+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "veloxis",
        "pharmaceutical",
        "veloxis",
        "pharmaceutical",
        "maintains",
        "outlook",
        "operating",
        "loss",
        "accounting",
        "stock",
        "compensation",
        "range",
        "usd",
        "million",
        "pharmaceutical",
        "announces",
        "financial",
        "result",
        "first",
        "three",
        "month",
        "qtrly",
        "product",
        "revenue",
        "q1",
        "tusd",
        "increase",
        "compared",
        "period",
        "last",
        "year",
        "veloxis",
        "maintains",
        "outlook",
        "revenue",
        "range",
        "usd",
        "usd",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}